Plexium

Nurix Therapeutics

This company develops targeted protein degradation therapies to treat patients with cancer and autoimmune diseases.

Biotheryx

The company develops protein degrader medicines for patients with cancer and inflammatory diseases.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

Amphista Therapeutics

This company develops targeted protein degradation medicines to treat patients with cancer and other diseases.

Arvinas

This biopharmaceutical company develops protein degradation therapies to treat patients with cancer and neurodegenerative diseases.

Sibylla Biotech

This company develops small molecule protein degraders for pharmaceutical partners and clinical research to treat oncological and neurodegenerative diseases.

UbiquiTx

This company develops a programmable protein modulation platform using artificial intelligence to create targeted therapies for pharmaceutical businesses and patients with complex diseases.

Enodia

This company develops small-molecule therapies that degrade disease-causing proteins at the point of synthesis for patients with cancer and inflammatory diseases.